Researchers have completed the largest study to date of TCF7L2-related neurodevelopmental disorder (TRND), a rare genetic condition caused by changes in the TCF7L2 gene, which plays an important role in brain development. By analyzing 76 patients from around the world in collaboration with sites across 14 countries and several US cities, including Philadelphia and Boston, the team found that the most common identifying features were speech delay, autism, developmental delays, vision problems such as nearsightedness, and orthopedic issues affecting the muscles and skeleton. Many patients also had distinctive facial features, helping researchers better define the condition and improve recognition and diagnosis. The study, led by Senior Author, David Fajgenbaum, MD, MBA, MSc, and other researchers in the Perelman School of Medicine at the University of Pennsylvania, was recently published in Genetics in Medicine.
“By defining the genetic and clinical features of TRND across a large international cohort, we hope to improve recognition of the condition and accelerate future research regarding longitudinal outcomes and potential therapies,” said first-author on the study Sally Nijim, MD, MBA, a resident physician-researcher at Mass General Brigham, who conducted the research while a medical student at Penn Medicine. The study also found that symptoms can vary widely and identified a possible link between certain TCF7L2 variants and type 2 diabetes in adults that warrants further study. The TRND Network is an initiative borne out of this study which connects TRND patients, families, physicians, and researchers, and a prospective natural history registry for longitudinal study of TRND patients is available to patients for enrollment ( https://trndnetwork.org/join-the-registry/ ).
###
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service.
The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine , founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with more than $588 million awarded in the 2024 fiscal year. Home to a proud history of “firsts,” Penn Medicine teams have pioneered discoveries that have shaped modern medicine, including CAR T cell therapy for cancer and the Nobel Prize-winning mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System cares for patients in facilities and their homes stretching from the Susquehanna River in Pennsylvania to the New Jersey shore. UPHS facilities include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Doylestown Health, Lancaster General Health, Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, chartered in 1751. Additional facilities and enterprises include Penn Medicine at Home, GSPP Rehabilitation, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is a $13.7 billion enterprise powered by more than 50,000 talented faculty and staff.